Linzagolix
Indication
Treating moderate to severe symptoms of uterine fibroids (NICE TA996)
NICE TA996 - Linzagolix for treating moderate to severe symptoms of uterine fibroids
Amber level 0
Brand:
Nice TA:
996
Commissioning responsibility:
CCG
PbR excluded:
No
BNF chapter:
Endocrine system
Background
1.1 Linzagolix is recommended as an option for treating moderate to severe symptoms of uterine fibroids in adults of reproductive age only if:
- it is intended to be used for longer-term treatment (normally for more than 6 months and not for people who need short-term treatment, for example, before planned surgery)
- the following dosage is used:
- with hormonal add-back therapy (ABT): 200 mg once daily
- without hormonal ABT: 200 mg once daily for 6 months, then 100 mg once daily.
Recommendation
LSCMMG Recommendation:
Amber level 0
Reason for decision:
Suitable for GP prescribing following recommendation/initiation by specialist
Supporting documents: